Cancer News and Research

Latest Cancer News and Research

EMA recommends orphan drug designation for 4SC's resminostat to treat HCC

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended resminostat for designation as orphan medicinal product for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

26 Jul 2011

Erionite in North Dakota roads may increase risk of mesothelioma

As school buses drive down the gravel roads in Dunn County, North Dakota, they stir up more than dirt. The clouds of dust left in their wake contain such high levels of the mineral erionite that those who breathe in the air every day are at an increased risk of developing mesothelioma, a type of cancer of the membranes around the lungs, new research shows.

26 Jul 2011

Advaxis submits protocol revision for ADXS-HPV CIN Phase II study

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has submitted a protocol revision that has passed FDA review for the enrollment of the next 40 subject "mid strength" dose cohort in the dose-ranging Phase II study of ADXS-HPV, an immunotherapy for Cervical Intraepithelial Neoplasia.

26 Jul 2011

Women & Infants creates fully integrated center for high-risk pregnancy

Every pregnancy deserves special treatment. But when a woman with a normal pregnancy has a complication or a woman with a medical issue becomes pregnant, she needs highly specialized care.

26 Jul 2011

CRI announces new changes to cancer research funding programs

Cancer Research Institute, Inc. (CRI), a U.S. nonprofit organization established in 1953 to advance the science of tumor immunology and foster the discovery of new cancer immunotherapies, announced today new changes and additions to its research funding programs.

26 Jul 2011

BioSante second quarter net loss increases to $15.0 million

BioSante Pharmaceuticals, Inc. today announced its financial results for the second quarter of 2011.

26 Jul 2011

Adaptimmune announces opening of pilot clinical trial in synovial sarcoma

Adaptimmune announced today that it has opened a Pilot, open-label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland, testing its enhanced T cell receptor T cell therapy. A second site is planned to open later this year at Washington University, St. Louis, Missouri.

25 Jul 2011

Affordable cell transfer therapy for cancers

One of the latest attempts to boost the body's defenses against cancer is called adoptive cell transfer, in which patients receive a therapeutic injection of their own immune cells. This therapy, currently tested in early clinical trials for melanoma and neuroblastoma, has its limitations: Removing immune cells from a patient and growing them outside the body for future re-injection is extremely expensive and not always technically feasible.

25 Jul 2011

Fluoride supplements neither safe or effective

Sodium fluoride supplements "have not been found by FDA to be safe or effective," according to the U.S. National Library of Medicine's website, reports the New York State Coalition Opposed to Fluoridation, Inc..

25 Jul 2011

Genesis Biopharma partners with Lonza for Contego to treat metastatic melanoma

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer therapies, and Lonza, today announced the signing of a process development and scale-up agreement relating to the manufacture of Contego™, Genesis Biopharma's autologous cell therapy product candidate for the treatment of Stage IV metastatic melanoma.

25 Jul 2011

Threshold reports initiation of TH-302 and bevacizumab clinical trial for astrocytoma

Threshold Pharmaceuticals, Inc., today announced that the University of Texas at San Antonio initiated a clinical trial of TH-302 in combination with bevacizumab in patients with recurrent high grade astrocytoma including glioblastoma.

25 Jul 2011

Bionovo completes 13 weeks repeat dose animal toxicology studies for Menerba

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, announced today the successful completion of 13 weeks repeat dose animal toxicology studies with Menerba.

25 Jul 2011

Ranbaxy announces launch of Letrozole Tablets in UK, Romania and France

Ranbaxy Laboratories Limited today announced the launch of Letrozole Tablets 2.5 mg in UK, Romania and France, on Day-1. Letrozole is the bio equivalent of Femara, the innovator product of Novartis, that has a market size of USD 58 Mn in UK, USD 95 Mn in France and USD 5.5 Mn in Romania.

25 Jul 2011

BDSI completes BEMA Buprenorphine Phase 3 trial on chronic pain

BioDelivery Sciences International, Inc. announced today that the last patient has completed the randomized portion of its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain, signifying completion of the trial.

25 Jul 2011

Better targeting of pharmaceuticals to patient's genetic profile could save around $110B annually

Genetic testing made possible by the mapping of the human genome can help the US cut costs and create jobs while at the same time improving survival rates for such diseases as cancer, HIV, and heart disease.

25 Jul 2011

Mayo Clinic trial to evaluate folate receptor alpha-targeted breast/ovarian cancer vaccine

VaxOnco, a leading oncology biopharmaceutical company, today announced that following FDA IND approval, it will sponsor a Phase I folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic.

25 Jul 2011

New WHO policy recommendation warns against use of blood tests for active TB

A new policy recommendation released on 20 July by the World Health Organization (WHO) warns against the use of serological (blood) tests to diagnose active tuberculosis.

25 Jul 2011

Novalis Tx system for treatment of cancer goes into service today

A treatment system called the Novalis Tx has gone into service today, which has the ability to destroy cancerous cells virtually anywhere in the body in a single, 20-minute session, without the need for a single cut of the scalpel.

25 Jul 2011

Two genetic variations can identify children at higher risk of radiation-induced second cancers

A genome-wide association study published in the August issue of Nature Medicine has found two tiny genetic variations that can predict which patients with Hodgkin's lymphoma are most likely to develop radiation-induced second cancers years after treatment.

25 Jul 2011

Many doctors do not appropriately offer breast and ovarian cancer counseling

A new analysis has found that many doctors report that they do not appropriately offer breast and ovarian cancer counseling and testing services to their female patients. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to encourage these services for high-risk women and discourage them for average-risk women.

25 Jul 2011